News | February 23, 2022
Complement Therapeutics raises €5 million seed financing
Appoints Dr Rafiq Hasan as CEO
Appoints Dr Rafiq Hasan as CEO
New inhalers would have near-zero Global Warming Potential propellant
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Subscribe To Our Newsletter & Stay Updated
